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Abstract 
Introduction: Acute kidney injury (AKI) is a serious complication of cardiac surgery. The current ‘gold 
standard’ for determining AKI is change in serum creatinine and urine output, however, this change 
occurs relatively late after actual injury occurs. Identification of new biomarkers that detect early AKI 
is required. Recently new biomarkers, such as the NephroCheck® Test and AKIRisk have also been 
tested and found to be good indicators of AKI. Neutrophil gelatinase-associated lipocalin (NGAL) has 
shown promise in paediatric patients but has displayed varied results in adult populations, 
particularly post cardiac surgery. The aim of this study was to assess the value of urinary NGAL as a 
biomarker of AKI in patients with pre-existing renal impairment (eGFR >15ml/min to 
eGFR<60ml/min). 
Methods: A post-hoc analysis of urinary NGAL concentrations from 125 patients with pre-existing 
kidney impairment, who participated in a randomised trial of haemofiltration during cardiac surgery, 
was undertaken. Urinary NGAL was measured using ELISA at baseline, post-operatively and 24 and 
48 hours after surgery and serum creatinine was measured pre and post operatively and then at 24, 
48, 72 and 96 hours as routine patient care. NGAL concentrations were compared in patients with 
and without AKI determined by changes in serum creatinine concentrations. A Kaplan-Meier plot 
compared survival for patients with or without AKI and a Cox proportional hazards analysis was 
performed to identify factors with the greatest influence on survival. 
Results: Following surgery 43% of patients developed AKI (based on KDIGO definition). Baseline 
urinary NGAL was not found to be significantly different between patients that did and did not 
develop AKI. Urinary NGAL concentration was increased in all patients following surgery, regardless 
of whether they developed AKI and was also significant between groups at 24 (p=0.003) and 48 
hours (p<0.0001). Urinary NGAL concentrations at 48 hours correlated with serum creatinine 
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concentrations at 48 hours (r=0.477, p<0.0001), 72 hours (r=0.488, p<0.0001) and 96 hours (r=0.463, 
p<0.0001). Urinary NGAL at 48 hours after surgery strongly predicted AKI (AUC=0.76; P=0.0001). A 
Kaplan-Meier plot showed that patients with postoperative AKI had a significantly lower 7-year 
survival compared with those without AKI. Postoperative urinary NGAL at 48 hours >156ng/mL also 
strongly predicted 7 year survival.   However, additive EuroSCORE, age, current smoking and post-
operative antibiotics usage were distinctly significantly more predictive of 7-year survival as 
compared with postoperative urinary NGAL at 48 hours >156ng/mL. 
Conclusions:  Our study demonstrated that postoperative urinary NGAL levels at 48 hours post-
surgery strongly predicts the onset or severity of postoperative AKI based on KDIGO classification in 
patients with preoperative kidney impairment and was also strongly related to 7-year survival. 
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Introduction 
Acute kidney injury (AKI) is a serious complication of cardiac surgery, and is one of the most common 
causes of AKI in the intensive care unit [1]. Up to 39% of patients have been reported to develop AKI 
depending on patient characteristics and the type of surgery they underwent [[2]. Patients that go 
on to develop AKI following cardiac surgery have an increased hospital stay, increased risk of chronic 
kidney disease and an increased risk of death within 5 years post-surgery [3].  
The development of postoperative AKI is known to be driven by a number of intraoperative factors 
such as decreased renal perfusion, embolic events, cardiopulmonary bypass-induced inflammation, 
nephrotoxins and reperfusion injury [4-6] [16-18].  Studies have shown that only about 1% of cardiac 
surgery patients that develop severe postoperative AKI receive dialysis peri-operatively [7] [19]. It 
has been estimated that over 15% of patients develop postoperative AKI [8-11] [20-23]. Although 
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these patients are not treated with dialysis they are still at a higher risk of short- and long-term 
mortality, a longer hospital stay, and higher health care costs [8-11] [20-23]. The current ‘gold 
standard’ for kidney injury is based on changes in serum creatinine, however, this is a marker of 
kidney function and changes are only detected relatively late after actual injury occurs. As such, new 
markers that can identify post-operative AKI earlier are required.  
Changes in serum creatinine concentrations are currently the ‘gold standard’ in assessing kidney 
injury. However, changes in serum creatinine occur as a result of the functional change in glomerular 
filtration rate, due to structural changes that occur during the early stage of kidney injury. As such, 
these changes can only be detected relatively late after the initial injury occurs. It can also be 
influenced by several factors in the absence of kidney injury including age, gender, muscle mass, 
muscle metabolism, medications, hydration status, nutrition status and tubular secretion. As a result 
there is a need for clinical biomarkers that can detect AKI earlier, and more accurately, so that 
supportive therapy can be initiated in a time effective manner to the right patients. Many of these 
new biomarkers have concentrated on biomarkers of tubular injury such as neutrophil gelatinase-
associate lipocalin (NGAL).  
NGAL is a small, 25kDa, protein that is rapidly up-regulated and excreted following acute tubular 
damage [12-13] and can be detected in both plasma and urine early in the process of kidney injury. 
Studies in paediatric patients have indicated that a rise in NGAL can be detected as soon as 2-6 hours 
following surgery in both serum and urine [14-15] and as such it would be a useful biomarker in 
evaluating and treating patients earlier, potentially leading to better outcomes. However, research 
in different adult populations has shown conflicting results [16-19]  , indicating that changes in 
serum biomarker concentrations are not necessarily related to decreased kidney function alone and 
can be the product of a systemic response [20]. In contrast, urine samples can be noninvasively 
collected, contain a reduced number of interfering proteins, and may have higher specificity for 
kidney damage irrespective of systemic pathology [21]. The aim of this study was therefore, to 
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assess the value of NGAL as a biomarker of AKI in patients with pre-existing renal impairment (eGFR 
<60ml/min) following cardiac surgery. 
Methods 
In total 199 patients were recruited into a randomised trial of haemofiltration on bypass [20]. In this 
post-hoc analysis, 74 patients were excluded due to incomplete sample sets. All participants gave 
written informed consent.  Men and women at least 18 years old were included if they were high-
risk patients undergoing elective surgery for on-pump surgery, i.e. valve replacement, coronary 
artery bypass graft (CABG) or combined CABG and valve procedures. They had an impaired renal 
function established pre-operatively by an eGFR <60ml/min. Patients were recruited from the 
routine waiting list for cardiac operations and were pre-screened for inclusion/exclusion criteria. 
Patients were excluded if they were scheduled to undergo surgery with anticipated CPB time less 
than 60 minutes, undergoing surgery on the great vessels (aortic surgery, had impaired liver function 
(serum bilirubin >60 or INR >2 without anticoagulation), patients further down the line of renal 
failure (eGFR <15ml/min) or were on dialysis, had malignancy or those that were pregnant. Informed 
patient consent was obtained from patients attending their routine pre-operative appointments, 
according to the protocol approved by the National Research Ethics Service, Northwest 4 Research 
Ethics Committee UK, and conducted in accordance with the Declaration of Helsinki and the 
European Union Clinical Trials Directive 2001/20/EC. Details of the surgical and anaesthetic protocols 
are as described previously [22].  
 
Anaesthesia 
Anaesthetic management was as per individual consultant’s preference. All anaesthetics were 
opioid-based with anaesthesia being induced with either a benzodiazepine or propofol (AstraZeneca, 
London, UK). Muscle relaxation was maintained with Vecuronium (Merck, Sharp & Dohme, Ltd, 
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Hertfordshire, UK) and anaesthesia was maintained using isoflurane (Baxter UK, Newbury, Berkshire, 
UK) in oxygen/air. Depth of anaesthesia was monitored continuously in all patients using bispectral 
index-monitoring. Inotrope requirements were at the discretion of the individual consultants, but all 
inotropes used were recorded within the case record 
Surgery  
In all cases, cardiopulmonary (CPB) bypass surgery was performed through a median sternotomy. 
Myocardial protection was based on surgical preferences, with a choice between intermittent cold 
blood and intermittent cold crystalloid cardioplegia. The delivery route was antegrade only or 
antegrade followed by retrograde. Some surgeons preferred to complete all anastomoses proximal 
and distal while the aortic cross clamp was still on. Others preferred to do the proximal anastomoses 
with just a side clamp on (once the aortic cross clamp has been removed) and some used a variation 
of the above depending on the number of grafts and condition of the aorta. A standard 1.3 m2 
haemofiltration set was used for Z-BUF kit that was supplied by Chalice Medical, UK (Worksop, 
Nottinghamshire) and connected to the pump. 
 
Critical care unit 
Patients were admitted and cared for in the immediate perioperatively period in the Intensive care 
unit (ICU). Indications for postoperative haemofiltration were: hyperkalaemia (potassium >6.0 
mmol/L); metabolic acidosis of renal origin; and anuria or oliguria urine output of less than 20 
ml/hour for more than 6 hours (despite adequate filling and adequate cardiac output) resulting in 
clinically significant fluid overload. The choice of use of inotropes and their duration was left to the 
discretion of ICU clinicians who also made the clinical decisions regarding appropriate time to 
discharge patients from the ICU. In-patients’ follow-up monitoring started on the day of surgery until 
hospital discharge or up to the 30th day of consecutive hospital stay before discharge. 
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Sample collection and measurements 
At least 10ml of urine was collected for biomarker analysis from patients at 4 time points: prior to 
surgery, within 6 hours on ICU and at 24 and 48 hours post-operatively. The samples were 
centrifuged at 1000xg for 10 minutes, aliquoted and frozen at -80°C for further analysis. Urinary 
NGAL concentrations were then measured using commercial enzyme-linked immunosorbent assay 
(ELISA) kits manufactured by BioPorto Diagnostics A/S, Hellerup, Denmark.   
Peripheral venous blood samples for serum creatinine analysis were collected prior to surgery, post-
operatively after ICU admission and at 24, 48, 72 and 96 hours after surgery. Serum creatinine 
concentrations were measured using routine clinical analysis in our UK accredited clinical pathology 
laboratory. 
 
Outcome measures 
1. Acute Kidney Injury (AKI):  Urinary NGAL levels were determined to assess predictive value for 
postoperative AKI. AKI was determined based on the definition of the international Kidney 
Disease Improving Global Outcomes (KDIGO) staging classification [23]. AKI is defined as an 
acute rise in serum creatinine from the preoperative value (obtained in the 30-day period before 
surgery) [22], where an acute rise is defined as values ≥26.5 μmol/L in the first 48 hours after 
surgery or ≥50% in the first 7 days after surgery. Briefly AKI was graded as follows based on 
changes in serum creatinine: 
Stage 1- serum creatinine increase of 1.5–1.9 times baseline value or an increase of ≥0.3 mg/dL 
(≥ 26.52 µmol/L). 
Stage 2 – serum creatinine increase 2.0–2.9 times baseline value. 
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Stage 3 – serum creatinine increase 3.0 times baseline, or increase in serum creatinine to ≥4.0 
mg/dL (≥353.6 µmol/L).  
The urine output criteria were not used as many patients required diuretics and/or haemofiltration 
the post-operative period. 
2. Follow-up survival:   Urinary NGAL levels were determined to assess predictive value for 
postoperative follow-up survival.  
Statistical analysis 
Statistical analysis was undertaken using SigmaPlot, SAS and StatsDirect software. Where there was 
non-Gaussian distribution, data was presented as median and range. Group differences were 
assessed using Kruskal Wallis, χ2 or Mann-Whitney U tests where appropriate. Spearman correlation 
was used to determine correlations for non-normal distribution data or categorical variables. Non-
normal distribution data was log-transformed to achieve normal distribution and analysed by 
Pearson correlation. A p<0.05 was considered statistically significant. Receiver Operating 
Characteristic (ROC) Curves were plotted to determine relationship between urinary NGAL and 
postoperative AKI. A Kaplan-Meier plot compared survival for patients with or without postoperative 
AKI and Cox proportional hazards regression model analysis was performed to identify factors with 
the greatest influence on survival. 
Results 
Patient characteristics 
Patients’ characteristics are summarised on Table 1. The median baseline urinary NGAL value in all 
patients was 23.00 (0.82-828.35) ng/mL. This was not found to be significantly different between 
current smokers 16.50 (4.41-725.36) ng/mL, ex-smokers 21.84 (1.44-828.35) or never-smoked 
patients 26.20 (0.82-655.46) ng/mL. There was also no difference detected between female and 
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male gender; 21.64 (0.82-806.53) and 21.84 (2.48-806.53) ng/ml respectively; or diabetic status; 
18.61 (0.82-806.53) and 29.81 (2.48-828.25) ng/ml for none-diabetics and diabetics respectively 
(Table 1).  
Postoperative outcomes 
Following surgery 43% of the patients went on to develop AKI as determined by serum creatinine 
and RIFLE criteria. Of these, 26 were in RIFLE class 1, 21 in class 2 and 7 in class 3 as summarised on 
Table 2. There was no significant difference between cross-clamp time or on pump time between 
the two groups during surgery and there was no difference in incidence of postoperative AKI in the 
haemofiltration or non-haemofiltration groups. Baseline urinary NGAL concentration was not found 
to be significantly different between AKI and NKI patients and the median urinary NGAL 
concentration (ng/ml) was significantly raised (p<0.0001) in all patients, at all the time points, 
following surgery regardless of whether they went on to develop AKI. Urinary NGAL concentration 
was significantly different between the two groups at both 24 hours (p=0.003) and 48 hours 
(p<0.0001) post-surgery (figure 1). Those patients that went on to develop postoperative AKI had a 
significantly longer ICU stay (p<0.0001) and hospital stay (<0.0001) compared to those patients 
without kidney injury.  
 
Correlations 
Baseline and post-surgery urinary NGAL did not correlate with serum creatinine at any time point. 24 
hour urinary NGAL concentrations weakly correlated with 24 hour (r=0.290, p=0.001130), 48 hour 
(r=0.274, p=0.0020), 72 hour (r=0.289, p =0.00179) and 96 hour (r=0.296, p=0.00261) serum 
creatinine. Whilst 48 hour urinary NGAL showed better correlations with 48 hour (r=0.477, 
p<0.0001), 72 hour (r=0.448, p<0.0001) and 96 hour (r=0.463, p<0.0001) serum creatinine (Figure 2). 
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 There was no correlation between the cross-clamp time or bypass time and NGAL concentration at 
any time point. However, there was a correlation between urinary NGAL concentration at 48 hours 
post-surgery and duration of ICU stay hours (r=0.265, p=0.00285). 
 
Receiver Operating Characteristic (ROC) Curves  
ROC curves demonstrated that baseline urinary NGAL levels for patients with preoperative kidney 
impairment scheduled to undergo cardiopulmonary bypass surgery do not significantly predict AKI, 
as determined by serum creatinine. In contrast, post-operatively, urinary NGAL values at 48 hours 
showed the most significant predictive value for AKI with an AUC = 0.76, sensitivity =0.7037 and 
specificity = 0.6901 and a cut-off value of >156ng/ml (Figure 3).  
 
Kaplan-Meier plot of 7-year follow-up survival  
As shown on Figure 4 patients with postoperative AKI had significantly lower 7-year follow-up 
survival compared with those without AKI (P=0.013). 
 
Cox proportional hazards regression model 
Table 2 shows a summary of a Cox proportional hazards model indicating that only age, current or 
past smoking, Urinary NGAL levels at 48h > 156 ng/mL and postoperative antibiotics usage were 
strong hazards for 7-year follow-up survival. The results indicate that patients with urinary NGAL 
levels at 48 h >156ng/mL have an 80% greater risk of death during the 7-year follow-up period 
compared to those with NGAL at 48 h <156 ng/mL, although statistical significance was not reached. 
In addition, the results shown on Table 3 also show that urinary NGAL levels at 48 h >156ng/mL is a 
much stronger predictor of survival than acute kidney injury. 
 
Discussion 
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This study has shown that for patients with preoperative kidney impairment postoperative urinary 
excretion of NGAL is elevated regardless of presence of AKI as assessed by KDIGO guidelines and 
RIFFLE Criteria [23]. Postoperatively only patients that develop AKI injury continue to present 
persistently elevated urinary NGAL at 24 hour time-point and beyond which may be indicative of late 
injury. The late injury may originate from an increased generation of free haemoglobin and iron 
through haemolysis are typically by-products of mechanical stresses that occur during 
cardiopulmonary bypass [24] mostly through cardiotomy suction, the duration of perfusion, 
occlusive roller pumps, turbulent flow in the oxygenator, and blood return through cell savers [24]. It 
has been shown previously [25] that the generation of free haemoglobin may contribute to oxidative 
stress and renal tubular injury [26].  Also low preoperative serum ferritin levels are associated with 
an increased risk for postoperative AKI [26]. Other potential contributors of late injury may include 
haemodilution [27-28] and the resultant decrease in oxygen carrying capacity [27-28]. Indeed, 
haemodilution (haematocrits ≤25%) is associated with an increased risk for renal injury as measured 
by changes in serum creatinine [29-30] which is thought to be due to the impairment of oxygen 
delivery to an already hypoxic renal medulla or to alterations in systemic inflammatory mediators 
caused by regional ischemia [30]. These are the potential mechanisms for the trigger of increased 
postoperative urinary NGAL excretion.  
NGAL is a 25kDa protein that is predominantly expressed in neutrophils [31]  and plays a role in iron 
metabolism [32]  and as a bacteriostatic agent [33].  It is also expressed at very low levels in several 
human tissues and is induced in injured epithelial cells, including the liver, lung, colon and kidney. 
Analysis from animal studies has shown NGAL to be one of the most highly induced proteins in the 
kidney following injury, and the fact it can be easily detected in urine shortly afterwards makes it a 
promising non-invasive clinical biomarker [34]. Several studies have since taken place in different 
clinical settings with mixed results [19-23].  Following cardiac surgery the results of these studies 
have been particularly variable and there is limited information for the use of NGAL in those patients 
that already have kidney disease, as this is an exclusion criterion in many studies. As such, we 
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decided to investigate whether urinary NGAL is a predictive biomarker of AKI in high risk patients 
with preoperative renal impairment (eGFR <50ml/min) undergoing cardiac surgery. 
We recruited 125 patients undergoing cardiac bypass surgery to our study, of which 43% developed 
AKI according to the KDIGO staging classification [23]. This incidence is higher than that commonly 
reported, but these were high risk patients who already had renal impairment, so a higher degree of 
kidney failure was to be expected. There was a significant increase in urinary NGAL in all patients at 
all time-points regardless of whether they went on to develop kidney injury. Despite this there was 
also a significant difference between the AKI and No-AKI groups at 24 and 48 hours. Furthermore, 24 
and 48 hour urinary NGAL correlated with serum creatinine concentrations at later time points. 
Unlike, previous studies, there was no correlation between both cross-clamp time and time on 
bypass and urinary NGAL concentration following surgery. Despite a significant difference between 
the AKI and No-AKI groups at 24 and 48 hours the AUC-ROC was best at 48 hours post-surgery but 
still did not provide adequate prediction of AKI, as determined by serum creatinine, for clinical 
purposes. 
The increase in urinary NGAL concentration in all patients regardless of time point or evolving 
preoperative AKI status suggests that an increase of NGAL from an extra-renal source is being 
observed. Animal models indicate that systemic NGAL filtered at the renal glomerulus is rapidly and 
efficiently reabsorbed by the proximal tubule (35). Whether or not this occurs in patients with 
chronic renal disease is unknown.   NGAL is synthesised in other tissues besides the kidney and plays 
a key-role in the inflammatory response. Patients undergoing CPB are likely to have a systemic 
inflammatory response following surgery, activating neutrophils and causing them to release their 
granular contents, including NGAL, into the circulation. NGAL has also been identified within the 
macrophages of atherosclerotic plaques (36,37), a disruption of which may release further NGAL into 
the circulation. This may explain why the predictive value of urinary NGAL increases over time in this 
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subset of patient and as the ‘noise’ from systemic inflammation following surgery decreases in 
patients without AKI, it remains elevated in those who have developed post-operative AKI. 
We also recognise in this study that assessing urinary NGAL against serum creatinine may not 
provide the best indicator of NGAL’s use as a biomarker. Serum creatinine is a marker of kidney 
function, whilst NGAL is a biomarker of tubular injury and is derived from epithelial cells undergoing 
proliferation and regeneration as part of the repair process. These differences in their characteristics 
mean that directly comparing the two may under represent NGAL’s value as a diagnostic marker of 
AKI. However, in the absence of another clinical biomarker of kidney injury the comparison between 
serum creatinine and NGAL concentrations will continue. Determination of urinary NGAL at 48 hours 
clinically could be important because levels >156ng/ml could be used to discriminate between the 
patients at high risk of developing further kidney injury, allowing for early within the first 24-48 
hours postoperatively. An early intervention for AKI may impact on long term survival of patients. 
Recently, there has been a focus on the development of new types of predictive tests based on 
panels of biomarkers. Such an approach is now being tested clinically, the latest being the 
NEPHROCHECK test system and AKIRisk score based on measurement of a panel of biomarkers 
consisting of tissue inhibitor metalloproteinase-2 [38] and Insulin-like growth factor binding protein-
7 [39], which are known to be involved in the responses to a variety of insults such as inflammation, 
oxidative stress, ultraviolet radiation, drugs and toxins [40-42]. We believe that the incorporation of 
urinary NGAL in the panel of biomarkers for acute kidney injury may in the future be useful in the 
enhancement of the specificity of such a test kit. The diagnostic performance of such a combination 
will require clarification on different patient populations before adoption of urinary NGAL into 
clinical practice becomes broadly acceptable. 
We acknowledge that this study, did not determine changes in haematocrit (oxygen carrying 
capacity) and intraoperative hypotension across the study period, mechanisms described previously 
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[27-30] as potential causes of postoperative kidney injury and whether this may relate to the level of 
urinary NGAL excretion.   
In conclusion, our study failed to show that baseline preoperative urinary NGAL predicts the onset 
and severity of AKI, based on KDIGO classifications, in patients with preoperative kidney disease. It is 
likely that the global systemic inflammatory response from bypass surgery triggers high levels of 
these markers such that the progression into kidney injury is masked by this event until 48 hours 
post-procedure where patients with AKI begin to emerge as having higher concentrations of urinary 
NGAL. It is highly probable that at 48 hours postoperative urinary NGAL not only indicate AKI but 
may also predict long term survival outcomes.  
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Tables 
Table 1: Patient characteristics 
 No-AKI (n=71) AKI (n=54) P-value 
Gender (female: male), 
n/n 
38/33  20/34 0.073 
Age, (median (range)) 
years 
75 (59-85) 74 (54-87) 0.458 
Intraoperative 
Haemofiltration 
33/71 (46.5) 
 
28/54 (51.9) 
 
0.560 
Post-operative 
Haemofiltration (n (%)) 
38 (54) 26 (48) 0.591 
Procedure type (n (%)) CABG = 21 (29.6) 
CABG + V = 16 (22.5) 
MVR = 12 (16.9) 
AVR = 22 (31) 
CABG = 16 (29.6) 
CABG + V = 21 (38.9) 
MVR = 3 (5.6) 
AVR = 14 (25.9) 
0.999 
0.051 
0.093 
0.557 
Diabetic, n (%) 20  (28.2) 22 (40.7) 0.900 
Smokers, n (%) Cigar =0(0) 
Current = 7 (9.9) 
Ex = 38 (53.5) 
Never =26 (36.6) 
Cigar = 1 (1.8) 
Current = 5 (9.3) 
Ex= 31 (57.4) 
Never = 17 (31.5) 
0.437 
0.999 
0.719 
0.574 
EuroSCORE II 2.97 (0.69-16.32) 3.94 (0.67-35.28) 0.034 
X-clamp time (min.) 75 (35-226) 78 (41-257) 0.980 
On pump time (min.) 106 (54-258) 115 (66-380) 0.720 
Baseline pre-operative 
urinary NGAL (ng/mL) 
21.64 (0.82-828.35) 23.58 (1.44-655.46) 0.913 
Post-operative urinary 
NGAL (ng/mL) on 
83.65 (0.52-1254.50) 149.89 (2.58-1141.30) 0.421 
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ICU= Intensive care unit 
 
Table 2: Perioperative Outcomes 
 Outcomes 
No-AKI  
(n=71) 
AKI  
(n=54) 
P-value 
In-hospital mortality 2 (2.8) 5 (9.3) 0.237 
Stroke 4 (5.6) 2 (3.7) 0.698 
Reoperation 9 (12.7) 4 (7.4) 0.339 
Prolonged ventilation (>48 hrs) 2 (2.8) 6 (11.1) 0.075 
Re-intubation 3 (4.2) 6 (11.1) 0.173 
Deep sternal wound infection 0 (0) 0 (0) - 
Acute Kidney Injury, n (%) 
RIFLE 1 
RIFLE 2 
RIFLE 3 
0 
0 
0 
26 
21 
7 
<0.0001 
ICU length of stay (days) 3 (2-26) 7 (2-93) <0.0001 
Post-operative length of stay (days) 9 (3-26) 15 (5-93) <0.0001 
ICU= Intensive care unit 
 
 
admission to ICU 
24 hours  Post-
operative urinary NGAL 
(ng/mL) 
143.24 (2.87-888.27) 237.61 (8.36-1154.37)  0.003 
48 hours postoperative 
urinary NGAL (ng/mL) 
93.92 (6.21-888.02) 288.93 (16.13-1048.00)  0.0001 
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Table 3:  Cox proportional hazards analysis for factors influencing 7-year survival  
Variable Hazard ratio 
95% confidence 
interval 
P-value 
Age (years) 1.056 1.011-1.102 0.010 
Female sex 1.602 0.842-3.050 0.150 
Diabetes 1.233 0.626-2.431 0.540 
Current smoker 3.271 1.080-9.902 0.040 
Ex-smoker 1.941 0.945-3.989 0.070 
NGAL (48hr) > 156 ng/mL 1.799 0.961-3.367 0.070 
Acute kidney injury 1.395 0.752-2.587 0.290 
Chest infection 1.549 0.730-3.286 0.250 
Postoperative antibiotics 
usage 
2.480 1.334-4.608 0.004 
ICU length of stay (hours) 1.000 0.999-1.001 0.810 
Postoperative antibiotic mean antibiotics given on suspicion of infection 
 
 
 
Figure legends 
22 
 
Figure 1: Urinary NGAL concentrations in patients with no acute kidney injury (NKI) versus acute 
kidney injury (AKI). Data is expressed as ng/ml. *P<0.05, **P<0.01, ***P<0.001. Statistical 
significance was determined using Kruskall-Wallis test. 
Figure 2: Correlation between 48 hour NGAL and serum creatinine concentration. Urinary NGAL 
concentration is expressed as ng/ml and serum creatinine as mg/L. Correlation was undertaken 
using Spearman Correlation test. 
Figure 3: Receiver operating characteristic curves for urinary NGAL in patients who developed 
post-operative AKI. Urinary NGAL concentrations were measured at baseline, post-surgery, and at 
24 and 48 hours following surgery. At baseline P=0.9127, post-surgery P=0.4209, 24 hours after 
surgery P=0.0032 and 48 hours following surgery P<0.0001. 
Figure 4: Analysis of association between long term survival and presence or absence of acute 
kidney injury using a Kaplan Meier plot.  
